TapImmune announces results from HER2/neu interim study on breast cancer
TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.